

Attorney Docket No.: ISPH-0795  
Inventors: Ackermann et al.  
Serial No.: 10/695,568  
Filing Date: October 27, 2003  
Page 2

This listing of claims will replace all prior versions, and  
listings, of claims in the application:

Listing of Claims:

Claims 1-20 (canceled).

Claim 21 (new): A method for activating a caspase signaling cascade in a cell comprising contacting a cell with an inhibitor of FLIP-c so that the at least one caspase is cleaved thereby indicating activation of a caspase signaling cascade.

Claim 22 (new): The method of claim 21, wherein the inhibitor of FLIP-c is a compound 15 to 25 nucleobases in length targeted to a nucleic acid molecule encoding FLIP-c, wherein said compound specifically hybridizes with and inhibits the expression of FLIP-c.

Claim 23 (new): The compound of claim 22 which is an antisense oligonucleotide.

Attorney Docket No.: **ISPH-0795**  
Inventors: **Ackermann et al.**  
Serial No.: **10/695,568**  
Filing Date: **October 27, 2003**  
Page 3

Claim 24 (new): The compound of claim 23, wherein the antisense oligonucleotide is chimeric or comprises at least one modified internucleoside linkage, sugar moiety, or nucleobase.

Claim 25 (new): The method of claim 21, wherein the caspase is caspase 3, caspase 7 or caspase 8.

Claim 26 (new): The method of claim 21, further comprising contacting the cell with TRAIL.